Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Mod Rheumatol ; 17(2): 144-7, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17437170

RESUMO

Relapsing polychondritis (RP) is a rare disease of unknown etiology causing systematic inflammation and resulting in destruction of cartilaginous tissues. We describe here an 18-year-old Japanese woman who developed severe airway stenosis as the initial symptom with auricular, nasal, and ocular inflammation. The effect of high dose oral steroid, methylprednisolone pulse therapy, and cyclophosphamide was temporary and her conditioning was worsening. Finally we added methotrexate to the immunosuppressive treatment and achieved reduction of disease activity. This case illustrates the potentially fatal sudden onset of airway inflammation that can occur with this disorder, and the effectiveness of methotrexate.


Assuntos
Ciclofosfamida/uso terapêutico , Imunossupressores/uso terapêutico , Metotrexato/uso terapêutico , Policondrite Recidivante/tratamento farmacológico , Adolescente , Antirreumáticos/uso terapêutico , Quimioterapia Combinada , Feminino , Humanos , Inflamação/etiologia , Metilprednisolona/uso terapêutico , Policondrite Recidivante/diagnóstico por imagem , Tomografia Computadorizada por Raios X
2.
Ann Rheum Dis ; 66(4): 470-5, 2007 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-17107983

RESUMO

AIM: Neuropsychiatric systemic lupus erythematosus (NPSLE) is a serious treatment-resistant phenotype of systemic lupus erythematosus. A standard treatment for NPSLE is not available. This report describes the clinical and laboratory tests of 10 patients with NPSLE before and after rituximab treatment, including changes in lymphocyte phenotypes. METHODS: Rituximab was administered at different doses in 10 patients with refractory NPSLE, despite intensive treatment. RESULTS: Treatment with rituximab resulted in rapid improvement of central nervous system-related manifestations, particularly acute confusional state. Rituximab also improved cognitive dysfunction, psychosis and seizure, and reduced the SLE Disease Activity Index Score at day 28 in all 10 patients. These effects lasted for >1 year in five patients. Flow cytometric analysis showed that rituximab down regulated CD40 and CD80 on B cells and CD40L, CD69 and inducible costimulator on CD4+ T cells. CONCLUSIONS: Rituximab rapidly improved refractory NPSLE, as evident by resolution of various clinical signs and symptoms and improvement of radiographic findings. The down regulation of functional molecules on B and T cells suggests that rituximab modulates the interaction of activated B and T cells through costimulatory molecules. These results warrant further analysis of rituximab as treatment for NPSLE.


Assuntos
Anticorpos Monoclonais/uso terapêutico , Antígenos CD20/sangue , Vasculite Associada ao Lúpus do Sistema Nervoso Central/tratamento farmacológico , Adulto , Anticorpos Monoclonais/efeitos adversos , Anticorpos Monoclonais Murinos , Linfócitos B/efeitos dos fármacos , Linfócitos B/imunologia , Feminino , Humanos , Imunofenotipagem , Vasculite Associada ao Lúpus do Sistema Nervoso Central/imunologia , Depleção Linfocítica/métodos , Subpopulações de Linfócitos/efeitos dos fármacos , Subpopulações de Linfócitos/imunologia , Pessoa de Meia-Idade , Rituximab , Índice de Gravidade de Doença , Resultado do Tratamento
3.
Clin Immunol ; 119(3): 297-306, 2006 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-16503201

RESUMO

Systemic lupus erythematosus (SLE) presents various clinical features; however, underlying mechanisms remain unclear. In the immunity of SLE, impaired T cell receptor (TCR) signaling and altered cytokine production are in the center of pathogenesis, although, little is known about NFAT (nuclear factor of activated T cells) in lupus T lymphocytes. TCR stimulation activates NFAT1 through Ca2+/calcineurin (Cn) pathway, facilitating nuclear translocation of NFAT1 from cytosol. Therefore, we investigated relationship of disease activity/features and intracellular NFAT1 localization in T lymphocytes from active lupus patients by fractionation. Results showed no significant relationship between disease activity and NFAT1 distribution. However, interestingly, we observed skewed NFAT1 distribution in pellet in patients with active lupus nephritis or pleuritis. In vitro cyclosporin A treatment suggested autonomously activated Ca2+/Cn pathway in lupus T lymphocytes. Considering these results, NFAT1 might be presenting the clinical heterogeneity in SLE.


Assuntos
Lúpus Eritematoso Sistêmico/metabolismo , Fatores de Transcrição NFATC/metabolismo , Linfócitos T/metabolismo , Adulto , Idoso , Ciclosporina/farmacologia , Feminino , Humanos , Proteínas I-kappa B/metabolismo , Masculino , Pessoa de Meia-Idade , Linfócitos T/efeitos dos fármacos
4.
J Bone Miner Res ; 19(1): 165-7, 2004 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-14753748

RESUMO

We experienced a 57-year-old female with adult-onset non-congenital idiopathic acro-osteolysis combined with proximal symphalangism. At the age of 36, she developed severe pain and swelling of the toe base of both feet and underwent Clayton surgery. However, the size of her toes diminished progressively over the 5-year period after surgery. At the age of 41, she suffered pain and swelling of the proximal interphalangeal (PIP) joints of fingers of both hands. These PIP joints became rigid and inflexible. Subsequently, she noticed shortening of the little finger of both hands, followed later by shortening of the index, middle, and ring fingers. At the age of 57, the thumbs began to shorten. Laboratory and endocrinological examinations were not abnormal. Finally, we diagnosed her with acro-osteolysis combined with proximal symphalangism by radiological examination. In this case, previously unreported mutations of the Noggin gene were identified. This is the first case report of adult-onset, non-congenital idiopathic acro-osteolysis combined with proximal symphalangism.


Assuntos
Acro-Osteólise/complicações , Deformidades Adquiridas do Pé/complicações , Deformidades Adquiridas da Mão/complicações , Acro-Osteólise/diagnóstico , Acro-Osteólise/patologia , Idade de Início , Proteínas de Transporte , Ácido Etidrônico/uso terapêutico , Feminino , Articulações dos Dedos/patologia , Deformidades Adquiridas do Pé/diagnóstico , Deformidades Adquiridas do Pé/patologia , Deformidades Adquiridas da Mão/diagnóstico , Deformidades Adquiridas da Mão/patologia , Humanos , Pessoa de Meia-Idade , Mutação de Sentido Incorreto/genética , Proteínas/genética , Deleção de Sequência/genética , Articulação do Dedo do Pé/patologia
5.
Clin Calcium ; 12(8): 1176-81, 2002 Aug.
Artigo em Japonês | MEDLINE | ID: mdl-15775417
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA